Takayo Matsumura

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki et al. · New England Journal of Medicine · 2020 · 353 citations · Full text

Medicine, Dermatology, Pharmacology +17

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki et al. · British Journal of Dermatology · 2021 · 126 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study

Atsuyuki Igarashi, Toshio Katsunuma, Takayo Matsumura et al. · British Journal of Dermatology · 2023 · 45 citations · Full text

Medicine, Dermatology, Pediatrics +17

Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years

Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura et al. · British Journal of Dermatology · 2024 · 18 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki et al. · Dermatology and Therapy · 2023 · 13 citations · Full text

Life Sciences, Dermatology, Pharmacotherapy +17